21 May 2013 - 21 May 2013 - US genome-mapping services and analyses provider Personal Genome Diagnostics said on Tuesday it had partnered with Blueprint Medicines to identify new kinase targets.

The partnership will utilise Personal Genome Diagnostics' methodologies and know-how in genomic analysis of defined cancer subtypes. Blueprint is focused on developing highly selective kinase inhibitors for a genetically defined patient population.

Blueprint's chief scientific officer Dr Christoph Lengauer said that the company is assessing various cancer subtypes that have not been examined before and that the company looks forward to working with Personal Genome Diagnostics to identify new and important aberrations.